INBUILD® Trial Population and Baseline Medications
15/03/2023 | Author: Boehringer Ingelheim
Document ID: PC-SG-101827
EFFICACY
RELATED CONTENT
![ofev-Consistent-efficacy-data-of-Ofev-in-all-severity-Infographic.png](/sg/sites/default/files/styles/bi_gds_card_style/public/2023-08/ofev-Consistent-efficacy-data-of-Ofev-in-all-severity-Infographic.png)
Consistent treatment effect of OFEV® irrespective of disease stage at which it is initiated
![ofev-Efficacy-in-FVC-less-than-or-equal-to-50-population-Infographic-190123.png](/sg/sites/default/files/styles/bi_gds_card_style/public/2023-08/ofev-Efficacy-in-FVC-less-than-or-equal-to-50-population-Infographic-190123.png)
OFEV® significantly reduces the risk of AE-IPF in the pooled INPULSIS®-1 and -2 and TOMORROW trials
![offv_slows_fvc_ decline_regardless_of_baseline_fvc_impairment_0.png](/sg/sites/default/files/styles/bi_gds_card_style/public/2023-08/offv_slows_fvc_%20decline_regardless_of_baseline_fvc_impairment_0.png)